Cancer medicines
Tarlatamab
Tarlatamab-dlle · Imdelltra
A bispecific T-cell engager that brings immune cells and cancer cells together.
Sources checked · Introductory guide
How does it work?
It binds DLL3 on cancer cells and CD3 on T cells, helping T cells attack the cancer.[1]
When is it used?
FDA traditional approval was granted on November 19, 2025, for adults with extensive-stage small cell lung cancer progressing on or after platinum-based chemotherapy.[2]
Safety to discuss before treatment
Boxed warnings cover cytokine release syndrome (CRS) and neurologic toxicity, including ICANS. Treatment starts with step-up dosing and monitoring. Report fever, breathing difficulty or confusion immediately.[3]
Check local access separately
US approval does not establish Korean approval, reimbursement or availability. Ask your treatment team about local access and cost.
Questions for your care team
- Is this medicine relevant to my treatment history and current condition?
- How should I prepare for monitoring and caregiver support?
Sources and scope
Source documents are in English.
- NCI · Tarlatamab-dlle (opens in a new tab)
- FDA · Traditional approval (2025-11-19) (opens in a new tab)
- DailyMed · IMDELLTRA prescribing information (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents.